{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T06:40:49Z","timestamp":1707115249814},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1053\/j.ackd.2006.04.005","type":"journal-article","created":{"date-parts":[[2006,7,7]],"date-time":"2006-07-07T19:20:15Z","timestamp":1152300015000},"page":"259-270","source":"Crossref","is-referenced-by-count":9,"title":["Optimizing Antimicrobial Therapy for Gram-Positive Bloodstream Infections in Patients on Hemodialysis"],"prefix":"10.1053","volume":"13","author":[{"given":"Amy Barton","family":"Pai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjunath P.","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2006.04.005_bib1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2005.05.024","article-title":"Tunneled catheters in hemodialysis patients","volume":"46","author":"Lee","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.04.005_bib2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1086\/501999","article-title":"Prospective surveillance for primary bloodstream infections occurring in Canadian hemodialysis units","volume":"23","author":"Taylor","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1053\/j.ackd.2006.04.005_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1525-139x.2000.00009.x","article-title":"Staphylococcus aureus bacteremia in patients undergoing hemodialysis","volume":"13","author":"Marr","year":"2000","journal-title":"Semin Dial"},{"key":"10.1053\/j.ackd.2006.04.005_bib4","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1001\/jama.293.24.3012","article-title":"Staphylococcus aureus endocarditis","volume":"293","author":"Fowler","year":"2005","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2006.04.005_bib5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1086\/502580","article-title":"Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis","volume":"26","author":"Engemann","year":"2005","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1053\/j.ackd.2006.04.005_bib6","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/01.ASN.0000119144.95922.C4","article-title":"Septicemia in the United States dialysis population, 1991 to 1999","volume":"15","author":"Foley","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2006.04.005_bib7","series-title":"USRDS 2003 Annual Data Report","year":"2003"},{"key":"10.1053\/j.ackd.2006.04.005_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1067\/mic.2002.120904","article-title":"New national surveillance system for hemodialysis-associated infections","volume":"30","author":"Tokars","year":"2002","journal-title":"Am J Infect Control"},{"key":"10.1053\/j.ackd.2006.04.005_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/499367","article-title":"Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003","volume":"42","author":"Klevens","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2006.04.005_bib10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1473-3099(05)70295-4","article-title":"The role of nasal carriage in Staphylococcus aureus infections","volume":"5","author":"Wertheim","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.ackd.2006.04.005_bib11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1086\/422458","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin","volume":"39","author":"Cosgrove","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2006.04.005_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10156-004-0307-5","article-title":"Glycopeptide resistance in Staphlyococcus aureus","volume":"10","author":"Gemmell","year":"2004","journal-title":"J Infect Chemther"},{"key":"10.1053\/j.ackd.2006.04.005_bib13","unstructured":"http:\/\/www.michigan.gov\/mdchlab Accessed 06-Jan-2006"},{"key":"10.1053\/j.ackd.2006.04.005_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00000441-200508000-00007","article-title":"Clinical characteristics of linezolid-resistant Staphylococcus aureus infections","volume":"330","author":"Peeters","year":"2005","journal-title":"Am J Med Sci"},{"key":"10.1053\/j.ackd.2006.04.005_bib15","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1128\/JCM.43.10.5285-5287.2005","article-title":"Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus","volume":"43","author":"Hayden","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1053\/j.ackd.2006.04.005_bib16","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1086\/520285","article-title":"Staphylococcus epidermidis","volume":"26","author":"Raad","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2006.04.005_bib17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1086\/502000","article-title":"Surveillance of hemodialysis-associated primary bloodstream infections","volume":"23","author":"Dopirak","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1053\/j.ackd.2006.04.005_bib18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1086\/502586","article-title":"Dynamics of hemodialysis catheter colonization by coagulase-negative staphylococci","volume":"26","author":"Fux","year":"2005","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1053\/j.ackd.2006.04.005_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1128\/CMR.15.2.167-193.2002","article-title":"Biofilms","volume":"15","author":"Donlan","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"10.1053\/j.ackd.2006.04.005_bib20","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1086\/318126","article-title":"Insights into the epidemiology and control of infection with vancomycin-resistant enterococci","volume":"31","author":"Hayden","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2006.04.005_bib21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1525-139X.2002.00051.x","article-title":"National surveillance of dialysis-associated diseases in the United States, 2000","volume":"15","author":"Tokars","year":"2002","journal-title":"Semin Dial"},{"key":"10.1053\/j.ackd.2006.04.005_bib22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of \u03b2-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1053\/j.ackd.2006.04.005_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s10156-003-0279-X","article-title":"Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling","volume":"9","author":"Nicolau","year":"2003","journal-title":"J Infect Chemother"},{"key":"10.1053\/j.ackd.2006.04.005_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1053\/j.ackd.2006.04.005_bib25","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/j.1875-9114.1997.tb03788.x","article-title":"Retrospective evaluation of therapies for Staphylococcus aureus endocarditis","volume":"17","author":"Gentry","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.ackd.2006.04.005_bib26","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0272-6386(01)80126-8","article-title":"Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers","volume":"37","author":"Sowinski","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"suppl","key":"10.1053\/j.ackd.2006.04.005_bib27","first-page":"63","article-title":"Killing and regrowth of bacteria in vitro","volume":"74","author":"Craig","year":"1990","journal-title":"Scand J Infect Dis"},{"key":"10.1053\/j.ackd.2006.04.005_bib28","series-title":"Product Information","year":"2003"},{"key":"10.1053\/j.ackd.2006.04.005_bib29","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/AAC.47.6.1853-1861.2003","article-title":"Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function","volume":"57","author":"Tam","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2006.04.005_bib30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002280050721","article-title":"Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis withhigh-flux membranes","volume":"56","author":"Schmaldienst","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.ackd.2006.04.005_bib31","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/ndt\/14.9.2265","article-title":"Cefepime-related neurotoxicity in a haemodialysis patient","volume":"14","author":"Wong","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2006.04.005_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/jac\/38.4.589","article-title":"The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions","volume":"38","author":"Larsson","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2006.04.005_bib33","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/01.CCM.0000178180.61305.1D","article-title":"Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides","volume":"33","author":"Rello","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1053\/j.ackd.2006.04.005_bib34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1128\/AAC.25.4.433","article-title":"Pharmacokinetics of vancomycin in patients with various degrees of renal function","volume":"25","author":"Matzke","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2006.04.005_bib35","first-page":"51","article-title":"Pharmacokinetics of vancomycin administered during high flux hemodialysis","volume":"50","author":"Foote","year":"1998","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2006.04.005_bib36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5414\/CNP60096","article-title":"Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers","volume":"60","author":"Mason","year":"2003","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2006.04.005_bib37","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/ajhp\/61.17.1812","article-title":"Vancomycin dosing in high flux hemodialysis","volume":"61","author":"Pai","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1053\/j.ackd.2006.04.005_bib38","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.ajkd.2005.07.018","article-title":"Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis","volume":"46","author":"Ariano","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2006.04.005_bib39","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1345\/aph.1G436","article-title":"Epidemiology of vancomycin-induced thrombocytopenia in patients receiving home intravenous infusion therapy","volume":"40","author":"Pai","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.ackd.2006.04.005_bib40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0891-5520(03)00057-6","article-title":"Pharmacodynamics and dosing of aminoglycosides","volume":"17","author":"Turnidge","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1053\/j.ackd.2006.04.005_bib41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jac\/49.3.437","article-title":"Role of aminoglycosides in the treatment of bacterial endocarditis","volume":"49","author":"Graham","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2006.04.005_bib42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2165\/00003088-200443030-00004","article-title":"Bayesian pharmacokinetics of gentamicin in a haemodialysis population","volume":"43","author":"Vercaigne","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.ackd.2006.04.005_bib43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.0894-0959.2004.17306.x","article-title":"Residual renal function","volume":"17","author":"Chandna","year":"2004","journal-title":"Semin Dial"},{"key":"10.1053\/j.ackd.2006.04.005_bib44","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00129492-200407000-00025","article-title":"Permanent gentamicin vestibulotoxicity","volume":"25","author":"Black","year":"2004","journal-title":"Otol Neurotol"},{"key":"10.1053\/j.ackd.2006.04.005_bib45","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.ackd.2006.04.005_bib46","first-page":"1136","article-title":"Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects","volume":"29","author":"Slatter","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1053\/j.ackd.2006.04.005_bib47","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1128\/AAC.47.9.2775-2780.2003","article-title":"Pharmacokinetics of linezolid in subjects with renal dysfunction","volume":"47","author":"Brier","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2006.04.005_bib48","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1097\/01.CCM.0000147687.06808.92","article-title":"Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure","volume":"32","author":"Fiaccadori","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1053\/j.ackd.2006.04.005_bib49","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/AAC.46.11.3484-3489.2002","article-title":"In vivo pharmacodynamics of a new oxazolidinone (linezolid)","volume":"46","author":"Andes","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2006.04.005_bib50","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemeia","volume":"56","author":"Shorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2006.04.005_bib51","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1086\/498509","article-title":"High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease","volume":"42","author":"Wu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2006.04.005_bib52","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1473-3099(04)01109-0","article-title":"Peripheral neuropathy associated with prolonged use of linezolid","volume":"4","author":"Bressler","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1053\/j.ackd.2006.04.005_bib53","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1345\/aph.1E523","article-title":"Serotonin toxicity associated with concomitant use of linezolid","volume":"39","author":"Bergeron","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.ackd.2006.04.005_bib54","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1086\/344177","article-title":"Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium","volume":"35","author":"Pai","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ackd.2006.04.005_bib55","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/ajhp\/62.11.1145","article-title":"Daptomycin","volume":"62","author":"Schriever","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1053\/j.ackd.2006.04.005_bib56","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","article-title":"Population pharmacokinetics of daptomycin","volume":"48","author":"Dvorchik","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2006.04.005_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2006.04.005_bib58","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jac\/dki422","article-title":"Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function","volume":"57","author":"Huang","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.ackd.2006.04.005_bib59","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/AAC.44.11.2948-2953.2000","article-title":"Once-daily dosing in dogs optimizes daptomycin safety","volume":"44","author":"Oleson","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.ackd.2006.04.005_bib60","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4065\/80.9.1215","article-title":"Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia","volume":"80","author":"Long","year":"2005","journal-title":"Mayo Clin Proc"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559506000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559506000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T06:21:58Z","timestamp":1707114118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559506000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S1548559506000607"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2006.04.005","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}